Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Carlos Cabrera-Gálvez"'
Autor:
Cristina Aguado, Ana Giménez-Capitán, Ruth Román, Sonia Rodríguez, Núria Jordana-Ariza, Andrés Aguilar, Carlos Cabrera-Gálvez, Carlos Rivas-Corredor, Pilar Lianes, Santiago Viteri, Irene Moya, Miguel A. Molina-Vila
Publikováno v:
Diagnostics, Vol 11, Iss 1, p 15 (2020)
The detection of ALK receptor tyrosine kinase (ALK), ROS proto-oncogen1, receptor tyrosine kinase (ROS1), ret proto-oncogen (RET), and MET proto-oncogen exon 14 skipping (METΔex14) allows for the selection of specific kinase inhibitor treatment in p
Externí odkaz:
https://doaj.org/article/0a4ea50edaa44fe884f0020201ecb8aa
Autor:
Miguel Angel Molina-Vila, Núria Jordana-Ariza, Santiago Viteri, Sonia Rodríguez, Ruth Román, Ana Giménez-Capitán, Andrés Aguilar, Cristina Aguado, Carlos Rivas-Corredor, Pilar Lianes, Irene Moya, Carlos Cabrera-Gálvez
Publikováno v:
Diagnostics
Volume 11
Issue 1
Diagnostics, Vol 11, Iss 15, p 15 (2021)
Volume 11
Issue 1
Diagnostics, Vol 11, Iss 15, p 15 (2021)
The detection of ALK receptor tyrosine kinase (ALK), ROS proto-oncogen1, receptor tyrosine kinase (ROS1), ret proto-oncogen (RET), and MET proto-oncogen exon 14 skipping (MET&Delta
ex14) allows for the selection of specific kinase inhibitor trea
ex14) allows for the selection of specific kinase inhibitor trea
Publikováno v:
Transl Lung Cancer Res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf820f238ab39d7f4eec654b4cd059ac
https://europepmc.org/articles/PMC7354136/
https://europepmc.org/articles/PMC7354136/
Autor:
N. Jordana Ariza, Rosa Rosell, M.A. Molina-Vila, Carlos Cabrera-Gálvez, B. García Peláez, Noemí Reguart, Erik d'Hondt, Jordi Codony-Servat, A. Aguilar-Hernández, Silvia Garcia-Roman, D. Rodriguez Abreu, Irene Moya, Santiago Viteri, Maria Gonzalez-Cao, M. Cobo
Publikováno v:
Journal of Thoracic Oncology. 16:S892
Introduction: Stage IIIB-IV non-small cell lung cancer patients with mutations in the EGF receptor gene (EGFR) usually derive clinical benefit from to tyrosine kinase inhibitors (EGFR TKIs) but ultimately relapse. In preclinical studies, we have show
Autor:
Clara Mayo-de-las-Casas, F. Rubinstein, A. Aguilar-Hernández, Rosa Rosell, A. Giménez Capitán, Sarah Warren, Irene Moya, Carlos González Pedraz, Magaly Molina, Maria Gonzalez-Cao, Santiago Viteri, Jillian Wilhelmina Paulina Bracht, P. Rubinstein, Carlos Cabrera-Gálvez, Joselyn Valarezo, Rich Boykin
Publikováno v:
Journal of Thoracic Oncology. 16:S1026
Autor:
Richard Boykind, Carlos González Pedraz, Clara Mayo-de-las-Casas, Jillian Wilhelmina Paulina Bracht, Carlos Cabrera-Gálvez, A. Aguilar-Hernández, Pablo Rubinstein, Alejandro Martinez-Bueno, Nicolas Potie, Maria Gonzalez-Cao, Miguel Ángel Molina-Vilaa, Chung-Ying Huang, Ana Gimenez Capitan, Rafael Rosell, Santiago Viteri, Sarah H. Warren, Joselyn Valarezo
Publikováno v:
Cancer Research. 81:2606-2606
Background: 80% of non-small cell lung cancer (NSCLC) cases are diagnosed at stages IIIB-IV and have a dismal prognosis with a median life expectancy that does not exceed 2 years. In contrast, patients diagnosed at early and locally advanced stages (